News
Dosing Initiation, Conferences Participation, Trial Results...
www.finanznachrichten.de
Matthew Wikler, MD, Vice President, Infectious Disease Care at The Medicines Company, said, "Our work with the SOLO trials is the first in a ...
Anti-infective assets - News Articleddn-news.com › ...
www.drugdiscoverynews.com
Rempex has given us leading programs for all three,” concluded Dr. Matthew Wikler, vice president, infectious disease care of The Medicines Company.
NEJM publishes results from SOLO I Phase 3 clinical trial of ORBACTIV...
www.news-medical.net
multiple-day dosing. "We are committed to perform relevant and robust research
and development of new anti-infective products," said Matthew Wikler, MD, Vice
President, Infectious Disease Care at The Medicines Company.
Pharma appointments, May PMLiVE
www.pmlive.com
Recent high-profile moves in the … and healthcare industries.
Mover of the month is Thomas Thorp who has been promoted to senior director of...
sorted by relevance / date